Health Condition 1: I708- Atherosclerosis of other arteries
Conditions
Interventions
Intervention1: Rosuvastatin-Ezetimibe-Bempedoic Acid: The drug combination will be given for 6 months and LDL reduction will be assessed at predefined intervals.
Control Intervention1: Rosuvastatin: I
Sponsors
Pahul Ahuja
Eligibility
Inclusion criteria
Inclusion criteria: Age more than 18 years Patients who were diagnosed as STEMI and have undergone PCI in preceding 24 hours before randomization LDL cholesterol measured within first 24 hours of admission to hospital Plasma triglycerides less than 350 mg per dl
Exclusion criteria
Exclusion criteria: Patients already treated with statins or other lipid medications Patients who were clinically unstable Subjects planned for or underwent CABG in response to initial episode of ACS Subjects planned for a Staged PCI Subjects who need to continue medications that have interaction with trial drugs Allergy/ sensitivity to Statin, Ezetimibe or Bempedoic Acid Renal dysfunction ( History of Chronic kidney disease and Egfr 2 times ULN) Pregnant or lactating woman or woman intending to become pregnant Uncontrolled hypothyroidism or TSH more than 1.5times ULN at enrolment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage LDL Reduction from baseline at 1 week, 2 week, 6 week, 3 month and 6 month Percentage patients achieving LDL-C target less than 55 mg/dl at 6 weeksTimepoint: 1 week, 2week, 6week, 3 month and 6 month | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of adverse effects due to drugs in 6 months follow up Occurrence of MACE in 6 months follow up Compare the LDL reduction with REB therapy at 3months to that observed in ORION trial with Statin + InclisiranTimepoint: 6months | — |
Countries
India
Contacts
Public ContactSandeep Bansal
VMMC and Safdarjung Hospital
Outcome results
None listed